A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure
Por:
Corma-Gomez, A, Macias, J, Rivero, A, Rivero-Juarez, A, de los Santos, I, Reus-Banuls, S, Morano, L, Merino, D, Palacios, R, Galera, C, Fernandez-Fuertes, M, Gonzalez-Serna, A, de Rojas, I, Ruiz, A, Saez, M, Real, L and Pineda, J
Publicada:
1 ago 2021
Ahead of Print:
20 ago 2021
Resumen:
Liver stiffness (LS) at sustained virological response (SVR) after direct-acting antivirals (DAA)-based therapy is a predictor of liver events in hepatitis C virus (HCV)-infected patients. The study aim was to identify genetic factors associated with LS changes from the moment of starting anti-HCV therapy to SVR. This prospective study included HCV-infected patients from the GEHEP-011 cohort who achieved SVR with DAA-based therapy, with LS pre-treatment >= 9.5 kPa and LS measurement available at SVR. Plink and Magma software were used to carry out genome-wide single-nucleotide polymorphism (SNP)-based and gene-based association analyses, respectively. The ShinyGO application was used for exploring enrichment in Gene Ontology (GO) categories for biological processes. Overall, 242 patients were included. Median (quartile 1, quartile 3) LS values at pre-treatment and at SVR were 16.8 (12, 28) kPa and 12.0 (8.5, 19.3) kPa, respectively. Thirty-five SNPs and three genes reached suggestive association with LS changes from the moment of starting anti-HCV therapy to SVR. GO categories related to DNA packaging complex, DNA conformation change, chromosome organization and chromatin organization were significantly enriched. Our study reports possible genetic factors associated with LS changes during HCV-infection cure. In addition, our results suggest that processes related to DNA conformation are also involved in these changes.
Filiaciones:
Corma-Gomez, A:
Hosp Valme, Unidad Clin Enfermedades Infecciosas & Microbiol, Seville 41014, Spain
Macias, J:
Hosp Valme, Unidad Clin Enfermedades Infecciosas & Microbiol, Seville 41014, Spain
Univ Seville, Dept Med, Seville 41009, Spain
Rivero, A:
Univ Cordoba, Unidad Enfermedades Infecciosas, Hosp Univ Reina Sofia, Inst Maimonides Invest Bionand Cordoba IMIBIC, Cordoba 14004, Spain
Rivero-Juarez, A:
Univ Cordoba, Unidad Enfermedades Infecciosas, Hosp Univ Reina Sofia, Inst Maimonides Invest Bionand Cordoba IMIBIC, Cordoba 14004, Spain
de los Santos, I:
Hosp La Princesa, Unidad Med Interna & Enfermedades Infecciosas, Madrid 28006, Spain
:
Hosp Gen Univ Alicante, Unidad Enfermedades Infecciosas, Alicante 03010, Spain
Morano, L:
Hosp Univ Alvaro Cunqueiro, Unidad Patol Infecciosa, Inst Invest Sanitaria Galicia Sur IISGS, Vigo 36312, Spain
Merino, D:
Hosp Univ Juan Ramon Jimenez, Unidad Enfermedades Infecciosas, Huelva 21005, Spain
Palacios, R:
Hosp Virgen de la Victoria, Unidad Enfermedades Infecciosas & Microbiol, Malaga 29010, Spain
Galera, C:
Hosp Clin Univ Virgen de la Arrixaca, Unidad Med Interna, Murcia 30120, Spain
Fernandez-Fuertes, M:
Hosp Valme, Unidad Clin Enfermedades Infecciosas & Microbiol, Seville 41014, Spain
Gonzalez-Serna, A:
Hosp Valme, Unidad Clin Enfermedades Infecciosas & Microbiol, Seville 41014, Spain
de Rojas, I:
Univ Int Catalunya UIC, Fundacio ACE, Inst Catala Neurociencies Aplicades, Barcelona 08028, Spain
Inst Salud Carlos III, CIBERNED Ctr Invest Bionand Red Enfermedades Neur, Madrid 28029, Spain
Ruiz, A:
Univ Int Catalunya UIC, Fundacio ACE, Inst Catala Neurociencies Aplicades, Barcelona 08028, Spain
Inst Salud Carlos III, CIBERNED Ctr Invest Bionand Red Enfermedades Neur, Madrid 28029, Spain
Saez, M:
Ctr Andaluz Estudios Bioinformat CAEBI SL, Seville 41013, Spain
Real, L:
Hosp Valme, Unidad Clin Enfermedades Infecciosas & Microbiol, Seville 41014, Spain
Univ Malaga, Dept Especialidades Quirurg Bioquim & Inmunol, Malaga 29010, Spain
Pineda, J:
Hosp Valme, Unidad Clin Enfermedades Infecciosas & Microbiol, Seville 41014, Spain
Univ Seville, Dept Med, Seville 41009, Spain
gold, Green Published
|